Improving Lives Through

Diagnostic and
Therapeutic Solutions

AXIM is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19)

Improving Lives Through

Diagnostic and
Therapeutic Solutions

AXIM’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived cannabinoid and oncological therapeutics.

COVID-19 TESTING

AXIM Biotechnologies has developed the first rapid (10-minute) point-of-care test that measures the concentration of neutralizing antibodies to COVID-19.

CLINICAL therapeutics

AXIM’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market 

CANCER dIAGNOSTICS

AXIM is in development of various “point-of-care” diagnostic testing products designed for the early detection of cancer

The Latest On Our Research

Founded in 2014, AXIM® Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on changing diagnosis and treatment for oncology and SARS-CoV-2 (COVID-19). AXIM’s NeuCovix is the first rapid diagnostic test measuring levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells. Additionally, the Company is developing rapid diagnostic tests for the early detection of cancer and proprietary small molecules drugs to treat cancer and block metastasis.